ConductScience.org, home

Paper31190820

Hypoxia-active nanoparticles used in tumor theranostic.

Wang Y and 4 others. Int J Nanomedicine, 2019. Cited by 53 papers, by iCite.

Cite this record

ConductScience Library. Hypoxia-active nanoparticles used in tumor theranostic. Papers, record 31190820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31190820

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hypoxia-active nanoparticles used in tumor theranostic.
PubMed
Journal
Int J Nanomedicine
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
53
iCite
Relative citation ratio, by iCite
2.27
iCite
Revised in PubMed
2020-02-25
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang YYaqin
2Shang WWenting
3Niu MMeng
4Tian JJie
5Xu KKe

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NanoparticlesMajor topic
Theranostic NanomedicineMajor topic
Tumor HypoxiaMajor topic
Diagnostic Imaging
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
Neoplasms

Source PubMed

Download CSV of topics

References139

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110476219PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery.Gene Ther1999https://conductscience.org/library/papers/10476219PubMed
211283581A clearer vision for in vivo imaging.Nat Biotechnol2001https://conductscience.org/library/papers/11283581PubMed
3113414684-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin.Oncol Res2000https://conductscience.org/library/papers/11341468PubMed
411375747Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia.Curr Med Chem2001https://conductscience.org/library/papers/11375747PubMed
511472243Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.Curr Med Chem2001https://conductscience.org/library/papers/11472243PubMed
611599887Effect of a hypoxic radiosensitizer, AK 2123 (Sanazole), on yeast Saccharomyces cerevisiae.J Radiat Res2001https://conductscience.org/library/papers/11599887PubMed
711705453Metabolism of tirapazamine by multiple reductases in the nucleus.Biochem Pharmacol2001https://conductscience.org/library/papers/11705453PubMed
811902584Hypoxia--a key regulatory factor in tumour growth.Nat Rev Cancer2002https://conductscience.org/library/papers/11902584PubMed
912234992Tirapazamine: a hypoxia-activated topoisomerase II poison.Cancer Res2002https://conductscience.org/library/papers/12234992PubMed
1012399448Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice.Physiol Genomics2002https://conductscience.org/library/papers/12399448PubMed
1112489027Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.Cancer Gene Ther2003https://conductscience.org/library/papers/12489027PubMed
1212859987Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress.Arch Biochem Biophys2003https://conductscience.org/library/papers/12859987PubMed
1313130303Targeting HIF-1 for cancer therapy.Nat Rev Cancer2003https://conductscience.org/library/papers/13130303PubMed
1414069241MITOMYCIN C: CHEMICAL AND BIOLOGICAL STUDIES ON ALKYLATION.Science1963https://conductscience.org/library/papers/14069241PubMed
1514162693MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA.Science1964https://conductscience.org/library/papers/14162693PubMed
1614654556NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.Clin Cancer Res2003https://conductscience.org/library/papers/14654556PubMed
1715642166The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone.Breast Cancer Res2005https://conductscience.org/library/papers/15642166PubMed
1815819391Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in human tumour cell lines.Arzneimittelforschung2005https://conductscience.org/library/papers/15819391PubMed
1916125243Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3.Neurotoxicology2006https://conductscience.org/library/papers/16125243PubMed
2016268634Synthesis and luminescence of soluble meso-unsubstituted tetrabenzo- and tetranaphtho[2,3]porphyrins.J Org Chem2005https://conductscience.org/library/papers/16268634PubMed

See all 139 referencesDownload CSV of references

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.

PMIDTitleJournalYearIn PapersSource
42226962Nanoparticle Drug Delivery Systems: The Future Direction for the Treatment of Tumors.Int J Nanomedicine2026https://conductscience.org/library/papers/42226962PubMed
41497307Hypoxia-responsive Exatecan prodrug liposomes co-delivered with IR808 for synergistic chemo-photodynamic therapy of breast cancer.Int J Pharm X2025https://conductscience.org/library/papers/41497307PubMed
40297580Immunocytes in the tumor microenvironment: recent updates and interconnections.Front Immunol2025https://conductscience.org/library/papers/40297580PubMed
39816693Hypoxia-responsive nanoparticles for fluorescence diagnosis and therapy of cancer.Theranostics2025https://conductscience.org/library/papers/39816693PubMed
39652186Cellular and molecular aspects of drug resistance in cancers.Daru2024https://conductscience.org/library/papers/39652186PubMed
39459028Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39459028PubMed
39281920Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies.ACS Omega2024https://conductscience.org/library/papers/39281920PubMed
39273657A Hypoxia-Decidual Macrophage Regulatory Axis in Normal Pregnancy and Spontaneous Miscarriage.Int J Mol Sci2024https://conductscience.org/library/papers/39273657PubMed
39179514Novel Prodrug Strategies for the Treatment of Tuberculosis.Chem Asian J2024https://conductscience.org/library/papers/39179514PubMed
38675218Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives.Pharmaceutics2024https://conductscience.org/library/papers/38675218PubMed
38675124Polymersomes as Innovative, Stimuli-Responsive Platforms for Cancer Therapy.Pharmaceutics2024https://conductscience.org/library/papers/38675124PubMed
38398021Tumor Microenvironment-Responsive Drug Delivery Based on Polymeric Micelles for Precision Cancer Therapy: Strategies and Prospects.Biomedicines2024https://conductscience.org/library/papers/38398021PubMed
37915127Stimuli-Responsive Nanotechnology for RNA Delivery.Adv Sci (Weinh)2023https://conductscience.org/library/papers/37915127PubMed
37841921Photodynamic therapy and associated targeting methods for treatment of brain cancer.Front Pharmacol2023https://conductscience.org/library/papers/37841921PubMed
37443821Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy.Cells2023https://conductscience.org/library/papers/37443821PubMed
37056346Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?Front Oncol2023https://conductscience.org/library/papers/37056346PubMed
36980778The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment.Cancers (Basel)2023https://conductscience.org/library/papers/36980778PubMed
36365094Mitophagy Induced by Metal Nanoparticles for Cancer Treatment.Pharmaceutics2022https://conductscience.org/library/papers/36365094PubMed
36295845Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia.Metabolites2022https://conductscience.org/library/papers/36295845PubMed
36096856Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.J Hematol Oncol2022https://conductscience.org/library/papers/36096856PubMed

See all 31 cited byDownload CSV of cited by

Genes26

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ARG1383PubTator's text mininghttps://conductscience.org/library/genes/383NCBI Gene
BAX581PubTator's text mininghttps://conductscience.org/library/genes/581NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CA9768PubTator's text mininghttps://conductscience.org/library/genes/768NCBI Gene
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CASP8841PubTator's text mininghttps://conductscience.org/library/genes/841NCBI Gene
CASP9842PubTator's text mininghttps://conductscience.org/library/genes/842NCBI Gene
CYP2B61555PubTator's text mininghttps://conductscience.org/library/genes/1555NCBI Gene
CYP4F34051PubTator's text mininghttps://conductscience.org/library/genes/4051NCBI Gene
GUSB2990PubTator's text mininghttps://conductscience.org/library/genes/2990NCBI Gene
HIF1A3091PubTator's text mininghttps://conductscience.org/library/genes/3091NCBI Gene
MRC14360PubTator's text mininghttps://conductscience.org/library/genes/4360NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
MTRR4552PubTator's text mininghttps://conductscience.org/library/genes/4552NCBI Gene
NDOR127158PubTator's text mininghttps://conductscience.org/library/genes/27158NCBI Gene
NOS24843PubTator's text mininghttps://conductscience.org/library/genes/4843NCBI Gene
NQO11728PubTator's text mininghttps://conductscience.org/library/genes/1728NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene

See all 26 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31190820

GET https://conductscience.org/api/papers/v1/31190820/references?page=2